Rigel co-founder, R&D staff jet­ti­soned in the long-await­ed lead up to an FDA pitch

Rigel didn’t quite man­age to con­vince an­a­lysts a cou­ple of weeks ago that its Syk in­hibitor was as ap­peal­ing as it made it out to be in a late-stage study for im­mune throm­bo­cy­tope­nia. But the biotech $RIGL is ab­solute­ly de­ter­mined to shift over to a com­mer­cial op­er­a­tion to back a prospec­tive fos­ta­ma­tinib launch, and it’s jet­ti­son­ing its re­search group to clear the way for the tran­si­tion, well ahead of any de­ci­sion from the FDA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER